Stocks · News reference
Zimmer Biomet Holdings, Inc. reported third quarter 2026 net sales of $2.063 billion and adjusted diluted earnings per share of $1.90, while updating its full-year 2026 financial guidance.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Multiple financial institutions, including Bernstein, RBC, Wells Fargo, and others, updated their price targets for Zimmer Biomet Holdings, Inc. on November 5, 2026, following the company's third-quarter earnings release.
JPMorgan has updated its price target for Zimmer Biomet Holdings, Inc., raising it from $117 to $120.
The ANZ dental implants market is valued at USD 266.0 million in 2025 and is projected to reach USD 393.0 million by 2033, growing at a 5.0% CAGR. Growth is driven by aging populations, increased demand for prosthetics, and technological advances in implant materials. However, high treatment costs remain a significant barrier to market expansion, with 28% of Australians delaying dental care due to affordability concerns.
Filed: 2026-11-04 AccNo: 0001193125-26-446145 Size: 2 MB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Surgical Planning Associates has added Zimmer Biomet implant systems to the preoperative 3D planning library of its HipInsight System, increasing the platform's compatibility for surgeons.
Zimmer Biomet Holdings, Inc. announced plans to host a featured symposium and showcase its latest digital and robotic technologies at the upcoming AAHKS 2026 annual meeting.